表紙
市場調查報告書
商品編碼
873283

瘧疾疫苗市場規模:各作用因素,各疫苗類型,各流通管道,各地區市場區隔及預測

Malaria Vaccines Market Size Report By Agent ; By Vaccines Type ; By Channel of Distribution ; By Regions Segments & Forecast, 2019 - 2026

出版日期: | 出版商: Polaris Market Research | 英文 210 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球瘧疾疫苗市場相關調查,市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業的簡介等相關資訊彙整。

第1章 概要與調查範圍

第2章 摘要整理

第3章 市場趨勢

  • 產業概要
  • 生態系統分析
  • 市場趨勢
  • 波特五力分析
  • PEST分析
  • 價值鏈分析
  • 產業趨勢
  • 競爭排行榜分析

第4章 各作用因素市場規模與預測

  • 調查結果
  • 熱帶熱瘧疾原蟲
  • 三日熱瘧疾平原
  • 瘧蚊種

第5章 各疫苗類型市場規模與預測

  • 調查結果
  • 前紅血球疫苗
  • 紅血球疫苗
  • 多重抗原疫苗

第6章 各流通管道市場規模與預測

  • 調查結果
  • 醫院
  • 診所
  • 社區中心

第7章 各地區市場規模與預測

  • 調查結果
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第9章 企業簡介

  • GlaxoSmithKline
  • GenVec, Inc.
  • Nobelpharma
  • Sanaria
  • Cadila Healthcare Ltd.
  • VLP Therapeutics LLC
  • CellFree Sciences Co. Ltd.
  • Genome ReS Ltd.
目錄
Product Code: PM1525

The global malaria vaccines market is expected to reach USD 134.9 million by 2026 growing at a CAGR of 33.2% during the forecast period according to a new study published by Polaris Market Research. The report 'Malaria Vaccines Market Size Report By Agent (Plasmodium Falciparum, Plasmodium Vivax, Anopheles Species); By Vaccines Type (Pre-Erythrocytic Vaccine, Erythrocytic Vaccine, Multi-antigen Vaccine); By Channel of Distribution (Hospitals, Clinics, Community Centers); By Regions: Segment Forecast, 2019 - 2026' provides an extensive analysis of present market dynamics and predicted future trends.

According to the World Malaria Report published by WHO in November 2018, the cases for malaria were 219 million in 2017 in more than 90 countries which were up from 217 million cases in 2017. The total deaths due to malaria in 2017 were 435,000 which were registered in the malaria affected regions.

This mosquito-borne illness creates extreme disease in kids and in grownups. Expecting females and kids cannot get away from consequences of this fever. It is reported that malaria-affected expecting females offer early birth or occasionally bring to life dead babies. Different precaution to suppress this fever consist of using insect nets and splashing of pesticides. Existing research studies have wrapped up that a) insects are immune to pesticides, b) pesticides have hazardous impacts to human beings, as well as c) malaria fever ends up being immune to medications. Actions to suppress malaria fever progressively reduces.

The market for malaria vaccines globally has been divided based on vaccine type, agent, channel of distribution and region. Considering the vaccine type, the market is bifurcated into pre-erythrocytic vaccine, erythrocytic vaccine, and multi-antigen vaccine. The channel of distribution used for malaria vaccines include the hospitals, clinics and community centers. Considering the agent used in the malaria vaccines, the global market is divided into plasmodium falciparum, anopheles species, and plasmodium vivax. Geographically, as per the WHO report, nearly half of the world's population was at risk in 2017, wherein the African region was the most affected one. Along with Africa, Asia Pacific region is also expected to grow at a considerable rate among all the other regions with Middle-east and Latin America likely to be the other potential regions for malaria vaccines market. North America and Europe have lower cases of malaria related diseases with regions such as Africa monitoring some of the highest deaths of children related to malaria globally.

Some of the major factors pushing the market include the expanding occurrences of malaria in addition to the existence of numerous companies that are introducing low profit margin vaccines throughout the world. Increasing awareness associated to the aftereffects of the disease, continuous R&D in this section and increased funding from the government of the developing and developed countries together is pushing the market for malaria vaccines globally. Weak supply chain and distribution network among some of the developing countries which are affected by malaria are creating restraints for the market growth in these regions, however companies and government organizations are working together to overcome this challenge. It is anticipated that the continuous R&D for malaria vaccines and the continuous growth of this disease will help the market to grow in the coming years.

A few key strategies adopted by companies operating in the malaria vaccines market are new technology and product development, and geographical expansion among the developing regions to focus on proving vaccines to the areas highly affected by the disease at lower cost. The leading players operating in the market globally are GlaxoSmithKline, GenVec, Inc., Nobelpharma, and Sanaria. Some other promising vendors are Cadila Healthcare Ltd., CellFree Sciences Co. Ltd., VLP Therapeutics LLC, and Genome ReS Ltd. among others.

Polaris Market Research has segmented the global malaria vaccines market on the basis of source type, application and region:

Malaria Vaccines Agent Type Outlook (Revenue, USD Million, 2015 - 2026)

Plasmodium Falciparum

Plasmodium Vivax

Anopheles Species

Malaria Vaccines Vaccine Type Outlook (Revenue, USD Million, 2015 - 2026)

Pre-Erythrocytic Vaccine

Erythrocytic Vaccine

Multi-antigen Vaccine

Malaria Vaccines Distribution Channel Type Outlook (Revenue, USD Million, 2015 - 2026)

Hospitals

Clinics

Community Centers

Malaria Vaccines Regional Outlook (Revenue, USD Million, 2015 - 2026)

North America

U.S.

Canada

Europe

Germany

UK

France

Rest of Europe

Asia-Pacific

China

India

Japan

Rest of Asia-Pacific

Latin America

Mexico

Brazil

Rest of LATAM

Middle East & Africa

Table of Contents

1. Overview and Scope

  • 1.1. Research goal & scope
  • 1.2. Research assumptions
  • 1.3. Research Methodology
    • 1.3.1. Primary data sources
    • 1.3.2. Secondary data sources
  • 1.4. Key take-away
  • 1.5. Stakeholders

2. Executive Summary

  • 2.1. Market Definition
  • 2.2. Market Segmentation

3. Malaria Vaccines Market Insights

  • 3.1. Malaria Vaccines- Industry snapshot
  • 3.2. Malaria Vaccines-Ecosystem analysis
  • 3.3. Malaria Vaccines market dynamics
    • 3.3.1. Malaria Vaccines- Market Forces
      • 3.3.1.1. Malaria Vaccines Market driver analysis
      • 3.3.1.2. Malaria Vaccines Market restraint/challenges analysis
      • 3.3.1.3. Malaria Vaccines Market opportunity analysis
  • 3.4. Industry analysis - Porter's five force
    • 3.4.1. Bargaining power of supplier
    • 3.4.2. Bargaining power of buyer
    • 3.4.3. Threat of substitute
    • 3.4.4. Threat of new entrant
    • 3.4.5. Degree of competition
  • 3.5. Malaria Vaccines market PEST analysis, 2017
  • 3.6. Malaria Vaccines market Value Chain analysis
  • 3.7. Malaria Vaccines Industry trends
  • 3.8. Competitive Ranking Analysis

4. Malaria Vaccines Market Size and Forecast by Agent

  • 4.1. Key Findings
  • 4.2. Plasmodium Falciparum
    • 4.2.1. Global Market Estimates and Forecasts, 2017-2026
  • 4.3. Plasmodium Vivax
    • 4.3.1. Global Market Estimates and Forecasts, 2017-2026
  • 4.4. Anopheles Species
    • 4.4.1. Global Market Estimates and Forecasts, 2017-2026

5. Malaria Vaccines Market Size and Forecast by Vaccines Type

  • 5.1. Key Findings
  • 5.2. Pre-Erythrocytic Vaccine
    • 5.2.1. Global Market Estimates and Forecasts, 2017-2026
  • 5.3. Erythrocytic Vaccine
    • 5.3.1. Global Market Estimates and Forecasts, 2017-2026
  • 5.4. Multi-antigen Vaccine
    • 5.4.1. Global Market Estimates and Forecasts, 2017-2026

6. Malaria Vaccines Market Size and Forecast by Channel of Distribution

  • 6.1. Key Findings
  • 6.2. Hospitals
    • 6.2.1. Global Market Estimates and Forecasts, 2017-2026
  • 6.3. Clinics
    • 6.3.1. Global Market Estimates and Forecasts, 2017-2026
  • 6.4. Community Centers
    • 6.4.1. Global Market Estimates and Forecasts, 2017-2026

7. Malaria Vaccines Market Size and Forecast by Regions

  • 7.1. Key findings
  • 7.2. North America
    • 7.2.1. Malaria Vaccines market by Agent, 2017 - 2026
    • 7.2.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
    • 7.2.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 7.2.4. U.S.
      • 7.2.4.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 7.2.4.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 7.2.4.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 7.2.5. Canada
      • 7.2.5.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 7.2.5.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 7.2.5.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
  • 7.3. Europe
    • 7.3.1. Malaria Vaccines market by Agent, 2017 - 2026
    • 7.3.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
    • 7.3.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 7.3.4. Germany
      • 7.3.4.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 7.3.4.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 7.3.4.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026

8.

  • 8.1.
    • 8.1.1. UK
      • 8.1.1.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 8.1.1.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 8.1.1.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 8.1.2. France
      • 8.1.2.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 8.1.2.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 8.1.2.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 8.1.3. Asia Pacific
      • 8.1.3.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 8.1.3.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 8.1.3.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 8.1.4. China
      • 8.1.4.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 8.1.4.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 8.1.4.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 8.1.5. India
      • 8.1.5.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 8.1.5.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 8.1.5.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 8.1.6. Japan
      • 8.1.6.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 8.1.6.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 8.1.6.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
  • 8.2. Latin America
    • 8.2.1. Malaria Vaccines market by Agent, 2017 - 2026
    • 8.2.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
    • 8.2.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 8.2.4. Brazil
      • 8.2.4.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 8.2.4.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 8.2.4.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
    • 8.2.5. Mexico
      • 8.2.5.1. Malaria Vaccines market by Agent, 2017 - 2026
      • 8.2.5.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
      • 8.2.5.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026
  • 8.3. Middle East & Africa
    • 8.3.1. Malaria Vaccines market by Agent, 2017 - 2026
    • 8.3.2. Malaria Vaccines market by Vaccines Type, 2017 - 2026
    • 8.3.3. Malaria Vaccines market by Channel of Distribution, 2017 - 2026

9. Company Profiles

  • 9.1. GlaxoSmithKline
    • 9.1.1. Overview
    • 9.1.2. Financials
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Developments
  • 9.2. GenVec, Inc.
    • 9.2.1. Overview
    • 9.2.2. Financials
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Developments
  • 9.3. Nobelpharma
    • 9.3.1. Overview
    • 9.3.2. Financials
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Developments
  • 9.4. Sanaria
    • 9.4.1. Overview
    • 9.4.2. Financials
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Developments
  • 9.5. Cadila Healthcare Ltd.
    • 9.5.1. Overview
    • 9.5.2. Financials
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Developments
  • 9.6. VLP Therapeutics LLC
    • 9.6.1. Overview
    • 9.6.2. Financials
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Developments
  • 9.7. CellFree Sciences Co. Ltd.
    • 9.7.1. Overview
    • 9.7.2. Financials
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Developments
  • 9.8. Genome ReS Ltd.
    • 9.8.1. Overview
    • 9.8.2. Financials
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Developments